These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

668 related articles for article (PubMed ID: 30737815)

  • 1. Bezafibrate Improves GLOBE and UK-PBC Scores and Long-Term Outcomes in Patients With Primary Biliary Cholangitis.
    Honda A; Tanaka A; Kaneko T; Komori A; Abe M; Inao M; Namisaki T; Hashimoto N; Kawata K; Takahashi A; Ninomiya M; Kang JH; Arakawa M; Yamagiwa S; Joshita S; Umemura T; Sato K; Kaneko A; Kikuchi K; Itakura J; Nomura T; Kakisaka K; Fujii H; Kawada N; Takikawa Y; Masaki T; Ohira H; Mochida S; Yoshiji H; Iimuro S; Matsuzaki Y; Takikawa H;
    Hepatology; 2019 Dec; 70(6):2035-2046. PubMed ID: 30737815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IgM response is a prognostic biomarker of primary biliary cholangitis treated with ursodeoxycholic acid and bezafibrate.
    Takano K; Saeki C; Oikawa T; Hidaka A; Mizuno Y; Ishida J; Takakura K; Nakano M; Torisu Y; Amano K; Ishikawa T; Zeniya M; Tsubota A; Saruta M
    J Gastroenterol Hepatol; 2020 Apr; 35(4):663-672. PubMed ID: 31677185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis.
    Tanaka A; Hirohara J; Nakano T; Matsumoto K; Chazouillères O; Takikawa H; Hansen BE; Carrat F; Corpechot C
    J Hepatol; 2021 Sep; 75(3):565-571. PubMed ID: 33882268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biochemical responses to bezafibrate improve long-term outcome in asymptomatic patients with primary biliary cirrhosis refractory to UDCA.
    Tanaka A; Hirohara J; Nakanuma Y; Tsubouchi H; Takikawa H
    J Gastroenterol; 2015 Jun; 50(6):675-82. PubMed ID: 25239675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis.
    Harms MH; van Buuren HR; Corpechot C; Thorburn D; Janssen HLA; Lindor KD; Hirschfield GM; Parés A; Floreani A; Mayo MJ; Invernizzi P; Battezzati PM; Nevens F; Ponsioen CY; Mason AL; Kowdley KV; Lammers WJ; Hansen BE; van der Meer AJ
    J Hepatol; 2019 Aug; 71(2):357-365. PubMed ID: 30980847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Fenofibrate Treatment in Primary Biliary Cholangitis Improves Biochemistry but Not the UK-PBC Risk Score.
    Hegade VS; Khanna A; Walker LJ; Wong LL; Dyson JK; Jones DEJ
    Dig Dis Sci; 2016 Oct; 61(10):3037-3044. PubMed ID: 27435324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fenofibrate normalizes alkaline phosphatase and improves long-term outcomes in patients with advanced primary biliary cholangitis refractory to ursodeoxycholic acid.
    Ding D; Ren P; Guo G; Liu Y; Yang C; Zheng L; Jia G; Deng J; Sun R; Wang X; Zhou X; Shang Y; Han Y
    Gastroenterol Hepatol; 2023 Nov; 46(9):692-701. PubMed ID: 36632973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fenofibrate improves GLOBE and UK-PBC scores and histological features in primary biliary cholangitis.
    Wang L; Sun K; Tian A; Liu Y; Zhang M; Zhou X; Han Y
    Minerva Med; 2022 Dec; 113(6):974-982. PubMed ID: 33949176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Additional fibrate treatment in UDCA-refractory PBC patients.
    Chung SW; Lee JH; Kim MA; Leem G; Kim SW; Chang Y; Lee HY; Yoon JS; Park JY; Lee YB; Cho EJ; Yu SJ; Kim YJ; Yoon JH
    Liver Int; 2019 Sep; 39(9):1776-1785. PubMed ID: 31162879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bezafibrate therapy in primary biliary cholangitis refractory to ursodeoxycholic acid: a longitudinal study of paired liver biopsies at 5 years of follow up.
    Sorda JA; González Ballerga E; Barreyro FJ; Avagnina A; Carballo P; Paes de Lima A; Daruich J
    Aliment Pharmacol Ther; 2021 Nov; 54(9):1202-1212. PubMed ID: 34587309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of Risk Scoring Systems in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis.
    Efe C; Taşçilar K; Henriksson I; Lytvyak E; Alalkim F; Trivedi H; Eren F; Eliasson J; Beretta-Piccoli BT; Fischer J; Calişkan AR; Chayanupatkul M; Coppo C; Ytting H; Purnak T; Muratori L; Werner M; Muratori P; Rorsman F; Önnerhag K; Günşar F; Nilsson E; Heurgué-Berlot A; Güzelbulut F; Demir N; Gönen C; Semela D; Aladağ M; Kiyici M; Schiano TD; Montano-Loza AJ; Berg T; Ozaslan E; Yoshida EM; Bonder A; Marschall HU; Wahlin S
    Am J Gastroenterol; 2019 Jul; 114(7):1101-1108. PubMed ID: 31241547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis.
    Cheung AC; Lammers WJ; Murillo Perez CF; van Buuren HR; Gulamhusein A; Trivedi PJ; Lazaridis KN; Ponsioen CY; Floreani A; Hirschfield GM; Corpechot C; Mayo MJ; Invernizzi P; Battezzati PM; Parés A; Nevens F; Thorburn D; Mason AL; Carbone M; Kowdley KV; Bruns T; Dalekos GN; Gatselis NK; Verhelst X; Lindor KD; Lleo A; Poupon R; Janssen HLA; Hansen BE;
    Clin Gastroenterol Hepatol; 2019 Sep; 17(10):2076-2084.e2. PubMed ID: 30616022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia.
    Hosonuma K; Sato K; Yamazaki Y; Yanagisawa M; Hashizume H; Horiguchi N; Kakizaki S; Kusano M; Yamada M
    Am J Gastroenterol; 2015 Mar; 110(3):423-31. PubMed ID: 25732417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of fenofibrate add-on therapy for patients with primary biliary cholangitis and a suboptimal response to UDCA.
    Duan W; Ou X; Wang X; Wang Y; Zhao X; Wang Q; Wu X; Zhang W; Ma H; You H; Jia J
    Rev Esp Enferm Dig; 2018 Sep; 110(9):557-563. PubMed ID: 29739227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis.
    Corpechot C; Chazouillères O; Belnou P; Montano-Loza AJ; Mason A; Ebadi M; Eurich D; Chopra S; Jacob D; Schramm C; Sterneck M; Bruns T; Reuken P; Rauchfuss F; Roccarina D; Thorburn D; Gerussi A; Trivedi P; Hirschfield G; McDowell P; Nevens F; Boillot O; Bosch A; Giostra E; Conti F; Poupon R; Parés A; Reig A; Donato MF; Malinverno F; Floreani A; Russo FP; Cazzagon N; Verhelst X; Goet J; Harms M; van Buuren H; Hansen B; Carrat F; Dumortier J;
    J Hepatol; 2020 Sep; 73(3):559-565. PubMed ID: 32275981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic scores for ursodeoxycholic acid-treated patients predict graft loss and mortality in recurrent primary biliary cholangitis after liver transplantation.
    Montano-Loza AJ; Lytvyak E; Hirschfield G; Hansen BE; Ebadi M; Berney T; Toso C; Magini G; Villamil A; Nevens F; Van den Ende N; Pares A; Ruiz P; Terrabuio D; Trivedi PJ; Abbas N; Donato MF; Yu L; Landis C; Dumortier J; Dyson JK; van der Meer AJ; de Veer R; Pedersen M; Mayo M; Manns MP; Taubert R; Kirchner T; Belli LS; Mazzarelli C; Stirnimann G; Floreani A; Cazzagon N; Russo FP; Burra P; Zigmound U; Houri I; Carbone M; Mulinacci G; Fagiuoli S; Pratt DS; Bonder A; Schiano TD; Haydel B; Lohse A; Schramm C; Rüther D; Casu S; Verhelst X; Beretta-Piccoli BT; Robles M; Mason AL; Corpechot C;
    J Hepatol; 2024 Oct; 81(4):679-689. PubMed ID: 38821360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ursodeoxycholic Acid Therapy in Patients with Primary Biliary Cholangitis with Limited Liver Transplantation Availability.
    Melchor-Mendoza YK; Martínez-Benítez B; Mina-Hawat A; Rodríguez-Leal G; Duque X; Moran-Villota S
    Ann Hepatol; 2017; 16(3):430-435. PubMed ID: 28425413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Geoepidemiology of Primary Biliary Cholangitis: Lessons from Switzerland.
    Terziroli Beretta-Piccoli B; Stirnimann G; Cerny A; Semela D; Hessler R; Helbling B; Stickel F; Kalid-de Bakker C; Bihl F; Giostra E; Filipowicz Sinnreich M; Oneta C; Baserga A; Invernizzi P; Carbone M; Mertens J
    Clin Rev Allergy Immunol; 2018 Apr; 54(2):295-306. PubMed ID: 29181702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The UK-PBC risk scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis.
    Carbone M; Sharp SJ; Flack S; Paximadas D; Spiess K; Adgey C; Griffiths L; Lim R; Trembling P; Williamson K; Wareham NJ; Aldersley M; Bathgate A; Burroughs AK; Heneghan MA; Neuberger JM; Thorburn D; Hirschfield GM; Cordell HJ; Alexander GJ; Jones DE; Sandford RN; Mells GF;
    Hepatology; 2016 Mar; 63(3):930-50. PubMed ID: 26223498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A validation study of the Ursodeoxycholic Acid Response Score in Japanese patients with primary biliary cholangitis.
    Yagi M; Matsumoto K; Komori A; Abe M; Hashimoto N; Inao M; Namisaki T; Kawata K; Ninomiya M; Fujii H; Takahashi A; Kang JH; Takamura M; Arakawa M; Joshita S; Sato K; Itakura J; Nomura T; Kakisaka K; Kaneko A; Tamura Y; Miura R; Aiso M; Arizumi T; Asaoka Y; Kikuchi K; Takikawa Y; Masaki T; Umemura T; Honda A; Ohira H; Kawada N; Yoshiji H; Mochida S; Takikawa H; Tanaka A;
    Liver Int; 2020 Aug; 40(8):1926-1933. PubMed ID: 32438508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.